



# Human Anti-Cemiplimab monoclonal antibody, clone AbD41947ad (CABT-ZB1156)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Specificity</b>	Cemiplimab
<b>Target</b>	Cemiplimab
<b>Immunogen</b>	Cemiplimab
<b>Isotype</b>	Fab
<b>Source/Host</b>	Human
<b>Species Reactivity</b>	N/A
<b>Clone</b>	AbD41947ad
<b>Affinity Constant</b>	The monovalent intrinsic affinity of AbD41947ad was measured as $K_D = 2$ nM by real time, label free molecular interaction analysis on immobilized cemiplimab.
<b>Purification</b>	Metal chelate affinity chromatography
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	Suitable for PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB1156 - CABT-ZB1158 Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
<b>Format</b>	Liquid
<b>Concentration</b>	Lot specific

<b>Size</b>	100 µg
<b>Buffer</b>	PBS
<b>Preservative</b>	0.1% ProClin 950
<b>Storage</b>	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
<b>Ship</b>	Wet ice

## BACKGROUND

**Introduction** Cemiplimab (Libtayo) is a fully human IgG4/kappa antibody. It has been approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) and for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression. Cemiplimab acts as a checkpoint inhibitor by binding to the PD-1 receptor and blocking its interaction with PD-L1 and PD-L2 ligands.

**Keywords** Cemiplimab; Libtayo